KRT19 and liver cancer: Patients with CK19 (+) primary liver tumor or CK 19(+) LN had significantly poorer overall survival than those without CK19 expression (for primary liver tumor, 9.37 ± 3.28 (2.942 to 15.798) months versus 28.96 ± 20.96 (0 to 70.039) months, P = 0.026, and for LN, 9.37 ± 3.17 (3.165 to 15.575) months versus 28.96 ± 12.92 (3.642 to 54.278) months, P = 0.007, respectively) (Figures 1 and2).